



Dedicated To Life

March 10, 2024

BSE Limited

P J Towers,
Dalal Street,
Mumbai-400001

Code: 532321

National Stock Exchange of India Limited

Exchange Plaza,
C/1, Block G,
Bandra-Kurla Complex, Bandra (East),
Mumbai-400051

Code: Zyduslife

Re.: Zydus receives EIR for the API Ahmedabad facility

Dear Sir / Madam,

We wish to inform that the company has received the EIR report from the USFDA for the inspection conducted at the API Ahmedabad facility. The company had earlier received Post Application Action Letter from the USFDA for the same inspection confirming that the inspected facility has been considered as ready to commercially manufacture and supply the API. This facility underwent an inspection from 14th to 22nd Dec 2023 and has been classified as Voluntary Action Indicated (VAI).

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Due to holidays the concerned executive was traveling and could not check the report. Hence, there is a delay in submission of the intimation.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,

For, **ZYDUS LIFESCIENCES LIMITED**

DHAVAL N. SONI

COMPANY SECRETARY

Zydus Lifesciences Limited (formerly known as Cadila Healthcare Limited)

Regd. Office : 'Zydus Corporate Park', Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad-382 481, Gujarat, India. | Phone : +91-79-71800000, +91-79-48040000
website : www.zyduslife.com | CIN : L24230GJ1995PLC025878

